Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
暂无分享,去创建一个
Wei Zheng | F. Ravandi | E. Jabbour | H. Khoury | G. Roboz | M. Arellano | E. Feldman | Wilena Session | S. Faderl | E. Ritchie | J. Morrison | H. Miao
[1] A. Zilberstein,et al. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias , 2013, Leukemia & lymphoma.
[2] J. Szer. The prevalent predicament of relapsed acute myeloid leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[3] S. Ohtake. [Current treatment of acute myeloid leukemia]. , 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[4] M. Baccarani,et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. , 2012, Blood.
[5] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Kantarjian,et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy , 2005, Cancer.
[7] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.